Eileen E. Ming
Eileen E. Ming has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Carl A. de Moor
Children’s Hospital Boston and Harvard Medical School
1 shared publication Carolyn G. Miles
AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 USA
1 shared publicationJames M. McKenney
National Clinical Research, Richmond, VA USA
1 shared publication- Lorenzo Cohen
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication Marcelo Marotti
AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom
1 shared publicationMichael H. Davidson
University of Chicago Pritzker School of Medicine, Chicago, IL USA
1 shared publication
Latest Publications
- Open Access
- 29 October 2008
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 2 (6) , 453-463
Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases
- 29 October 2008
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 2 (6) , 453-463
Open AccessConcomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases
- 14 November 2006
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (5) , 497-503
Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings
The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology settings. The effect of CINV on quality of life (QOL) was also evaluated. Cancer patients who were scheduled for their first cycle of a new chemotherapy regimen were recruited from ten community oncology clinics. Study participants recorded occurrence of CINV by completing a daily diary each day for the first 8 days after treatment during each cycle and the Functional Living Index-Emesis (FLIE) before chemotherapy, at the end of day 1 and day 6 after chemotherapy. Mixed model regression analysis was used to explore the association between occurrence of CINV at cycle 1 and subsequent cycles and its impact on patient QOL. One hundred and fifty-one patients provided information for at least one cycle. During cycle 1, only 33% had neither acute nor delayed CINV. Of the 36% patients who developed acute CINV, 8% developed acute CINV only. Of the 59% who developed delayed CINV, 53% reported delayed only and 47% reported acute and delayed CINV. A similar pattern was seen at cycles 2 and 3. Experience of CINV at cycle 1 was associated with the development of CINV at cycles 2 and 3. Occurrence of CINV significantly interfered with patient QOL as assessed by the FLIE. CINV remained a substantial problem for patients receiving chemotherapy in this community-based sample, especially delayed CINV. CINV significantly interfered with patient QOL and daily functioning.
- 14 November 2006
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (5) , 497-503
Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings
The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology settings. The effect of CINV on quality of life (QOL) was also evaluated. Cancer patients who were scheduled for their first cycle of a new chemotherapy regimen were recruited from ten community oncology clinics. Study participants recorded occurrence of CINV by completing a daily diary each day for the first 8 days after treatment during each cycle and the Functional Living Index-Emesis (FLIE) before chemotherapy, at the end of day 1 and day 6 after chemotherapy. Mixed model regression analysis was used to explore the association between occurrence of CINV at cycle 1 and subsequent cycles and its impact on patient QOL. One hundred and fifty-one patients provided information for at least one cycle. During cycle 1, only 33% had neither acute nor delayed CINV. Of the 36% patients who developed acute CINV, 8% developed acute CINV only. Of the 59% who developed delayed CINV, 53% reported delayed only and 47% reported acute and delayed CINV. A similar pattern was seen at cycles 2 and 3. Experience of CINV at cycle 1 was associated with the development of CINV at cycles 2 and 3. Occurrence of CINV significantly interfered with patient QOL as assessed by the FLIE. CINV remained a substantial problem for patients receiving chemotherapy in this community-based sample, especially delayed CINV. CINV significantly interfered with patient QOL and daily functioning.